Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
GSK CEO Strives to Resolve Zantac Litigation Drag on Shares
Categories: Zantac
GSK Plc’s CEO has made it a priority to ensure that the majority of the company’s employees remain focused on the company's core mission, rather than the ongoing…
J&J Files Third Bankruptcy to Resolve Talc Cancer Lawsuits
Categories: Talcum
In an effort to settle tens of thousands of ovarian cancer lawsuits linked to its talcum powder products, Johnson & Johnson has once again…
Baltimore to Sue Drug Distributors Over Opioid Crisis
Categories: Opioids
Baltimore is set to go to trial in its $11 billion lawsuit against drug distributors McKesson and Cencora (formerly AmerisourceBergen), accusing them of contributing to the…